ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib

Cell Death & Disease
Lei-Lei NiuPaul B S Lai

Abstract

Sorafenib is the only approved drug for the treatment of advanced hepatocellular carcinoma (HCC). However, its efficacy is limited by the emergence of primary and/or acquired resistance. Senescence-associated secretory phenotype (SASP)-mediated chemo-resistance, which depends on the secreted bioactive molecules, has attracted increasing attention but never revealed in HCC. In this study, we investigated the effect of SASP-related p16/IL6 axis on sorafenib resistance in HCC. Initially, we noticed that HCC cells with a high level of p16/IL6 axis exhibited a low sensitivity to sorafenib. Further in vivo and in vitro studies demonstrated that such a primary resistance resulted from ID1-mediated activation of p16/IL6 axis. Overexpression of ID1 or IL6 blocking in sorafenib-resistant HCC cells could increase the cytotoxicity of sorafenib. Moreover, SASP-related p16/IL6 axis contributed to the formation of acquired resistance in cells received long-term exposure to sorafenib. In acquired sorafenib-resistant cells, ID1 low expression, p16/IL6 axis up-regulation, and AKT phosphorylation activation were observed. A reduced cytotoxicity of sorafenib was detected when sorafenib-sensitive cells incubated with conditioned media from the resi...Continue Reading

References

Jun 28, 2001·Proceedings of the National Academy of Sciences of the United States of America·R M AlaniC B Shifflett
Jan 15, 2004·The Journal of Clinical Investigation·Pascal KahlemClemens A Schmitt
Jan 5, 2005·Nature Reviews. Cancer·Bruce A Chabner, Thomas G Roberts
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaLeonard B Saltz
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Jan 19, 2010·Annual Review of Pathology·Jean-Philippe CoppéJudith Campisi
Feb 17, 2010·Aging·Lars Zender, K Lenhard Rudolph
May 27, 2010·International Journal of Cancer. Journal International Du Cancer·Qin WangDaniel Y Wu
Jun 22, 2010·The Journal of Biological Chemistry·Yan LiuJiayuh Lin
Feb 16, 2011·The Journal of Cell Biology·Francis Rodier, Judith Campisi
Aug 6, 2011·Cancer Research·Benjamin G BitlerRugang Zhang
Oct 6, 2011·Journal of Hepatology·Uzma Asghar, Tim Meyer
Oct 26, 2011·International Journal of Cancer. Journal International Du Cancer·Hani RayessEri S Srivatsan
Nov 1, 2011·Seminars in Cancer Biology·Lars-Gunnar Larsson
Mar 1, 2012·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Ryan R Gordon, Peter S Nelson
Apr 20, 2012·International Journal of Cancer. Journal International Du Cancer·Zakaria EzzoukhryAntoine Galmiche
Aug 30, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Li-ping LiuPaul B S Lai
Jan 9, 2013·Methods in Molecular Biology·Yingjuan Qian, Xinbin Chen
Mar 19, 2013·Interdisciplinary Topics in Gerontology·Michael C VelardeJudith Campisi
Oct 19, 2013·Molecular Cancer Research : MCR·Kyle M LaPak, Christin E Burd
Jul 18, 2014·Nature Reviews. Cancer·Pedro A Pérez-ManceraMasashi Narita
Aug 11, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Dong-Xian GuanDong Xie
May 4, 2016·British Journal of Cancer·Pacome LecotChristopher Wiley

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
ELISA
transfection
xenograft
RNA-seq
PCR
Protein Assay

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.